rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ALLO
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Allogene at Jefferies conference: cema-cel gains ground in key trial
      17h agoInvesting.comALLOJEF
      Allogene reports early safety data for autoimmune CAR T therapy
      Nov 9Investing.comALLO
      Allogene Therapeutics Reports First Clinical Data from Phase 1 RESOLUTION Study of ALLO-329 in Autoimmune Disease
      Nov 9Yahoo FinanceALLO
      Allogene Therapeutics Inc (ALLO) (Q3 2026) Earnings Call Highlights: Alpha 3 Momentum Builds as ...
      Nov 6Yahoo FinanceALLO
      Allogene Therapeutics Q3 Earnings Call Highlights
      Nov 6Yahoo FinanceALLO
      Allogene Therapeutics Q3 2026 Earnings Call Transcript
      Nov 5BenzingaALLO
      Allogene Therapeutics: Q3 Earnings Snapshot
      Nov 5Yahoo FinanceALLO
      Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update

      Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL): ALPHA3 Enrollment Momentum Continues, Supported by Expanding Trial Network, Increased MRD Screening, and Brisk Enrollment in Asia-PacificNext ALPHA3 Clinical Update Anticipated in Mid-2027, with Trial Enrollment Completion Expected by Year-End 2027Appointed Cell Therapy Commercialization Veteran Rocio Manghani, MPH, as Vice President, Market Access, Evidence & StrategyInvestor Event at ASH to Focus on Cema-cel’s Potential to Over

      Nov 5Yahoo FinanceALLO
      Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting

      Two Invited Presentations Showcase Clinical Progress in Solid Tumors and Allogene's Broader Vision in Oncology and Autoimmune DiseasePreclinical Poster Features Next-Generation DLL3/CD70 Dual CAR T Product Candidate for Small Cell Lung Cancer and Other Neuroendocrine Tumors, Demonstrating Continued Innovation with Dagger® Technology SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the deve

      Nov 3Yahoo FinanceALLO
      Allogene schedules Q3 results and autoimmune therapy data release
      Oct 29Investing.comALLO
      Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

      SOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in the following upcoming investor conferences in November and December 2026. UBS Global Biopharma ConferenceMonday, November 16 11:20 AM GMT / 6:20 AM ET London Jefferies Global Healthcare ConferenceWednesday,

      Oct 26Yahoo FinanceALLO
      Allogene Therapeutics CFO Geoffrey Parker sells $48,698 in stock
      Oct 24Investing.comALLO
      Citizens reiterates Allogene stock rating on CAR T pipeline progress
      Sep 15Investing.comALLO
      Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?

      Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Sep 11Yahoo FinanceALLO
      Allogene at Citi summit: mrD strategy and cash runway in focus
      Sep 9Investing.comALLO
      Allogene Stock: If MRD Holds, This Becomes A Completely Different Company (NASDAQ:ALLO)

      Allogene Therapeutics maintains a $423.6M cash balance, disciplined cost controls, and a runway into 2029. Read why I rate ALLO stock a Buy.

      Sep 7Seeking AlphaALLO
      Allogene Therapeutics Announces Retirement of Chief Financial Officer

      Detailed price information for Allogene Therapeutics Inc (ALLO-Q) from The Globe and Mail including charting and trades.

      Sep 3The Globe and MailALLO
      Allogene CFO Geoffrey Parker to retire in November
      Sep 2Investing.comALLO
      Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker

      SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that Geoffrey Parker, Executive Vice President and Chief Financial Officer, will retire effective November 6, 2026. Mr. Parker will continue to lead the finance organization through his retirement date as the Company conducts an exter

      Sep 2Yahoo FinanceALLO
      Allogene Therapeutics CFO Geoffrey Parker to Retire

      Allogene Therapeutics (ALLO) said Wednesday that Chief Financial Officer Geoffrey Parker will retire

      Sep 2Yahoo FinanceALLO
      Allogene Therapeutics Announces Participation in September Investor Conference

      SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in the following upcoming investor conference in September. Citi Biopharma Back to School Conference Wednesday, September 9 5:00 a.m. PT/8:00 a.m. ET Any available webcasts will be posted to the Company’s websi

      Aug 31Yahoo FinanceALLO
      Allogene Therapeutics: Is The Market Looking At CAR-T Persistence The Wrong Way? (ALLO)
      Aug 28Seeking AlphaALLO

      This is the newest page. Registered accounts read further back.